Solriamfetol: First Global Approval
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01123-y
Abstract: Solriamfetol (Sunosi™) is an orally active, selective dopamine and norepinephrine reuptake inhibitor that was recently approved in the USA as a treatment for excessive daytime sleepiness (hypersomnia) associated with narcolepsy and obstructive sleep apnoea (OSA).… read more here.
Keywords: solriamfetol first; global approval; sleepiness; solriamfetol ... See more keywords